Abiopharma

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

New Form 8-K - ANI PHARMACEUTICALS INC Filed: 2025-07-23 AccNo: 0001023024-25-000072 Size: 206 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial ofILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

BD Announces First Pharma-Sponsored Clinical Trial Using BDLibertas™ Wearable Injector Technology for Biologic Drugs

Brookdale Senior Living Inc. - Brookdale Announces Second Quarter 2025 Earnings Release and Conference Call Dates

Brookdale Announces Second Quarter 2025 Earnings Release and Conference Call Dates

New Form 8-K - DuPont de Nemours, Inc. Filed: 2025-07-23 AccNo: 0001666700-25-000032 Size: 171 KB Item 7.01: Regulation FD Disclosure

New Form 8-K - BOSTON SCIENTIFIC CORP Filed: 2025-07-23 AccNo: 0000885725-25-000039 Size: 626 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.

U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates

Boston Scientific announces results for second quarter 2025